MIDDLE EAST AND ASIA PACIFIC ANTIBODY DRUGS MARKET ANALYSIS

Middle East and Asia Pacific Antibody Drugs Market, by Type (Monoclonal Antibodies, Polyclonal Antibody, Bispecific Antibody, Biosimilars, Single Domain Antibody, CAR-T, and Anti-idiotype Antibody), by Disease Indication (Oncology, Neurology, Autoimmune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (Middle East (Kingdom of Saudi Arabia, UAE, Israel, Iran, Jordan, Turkey, Qatar, and Rest of Middle East) and Asia Pacific (South East Asia, The Philippines, Malaysia, Singapore, Thailand, Vietnam, Rest of South East Asia, Taiwan, Hong Kong, Macau, Japan, South Korea, India, Australia, China, and Rest of Asia Pacific)) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Mar 2022
Code : CMI4952
Pages :242
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Adverse effects associated with the use of antibody drugs

Middle East and Asia Pacific Antibody Drugs Market: Restraint

Adverse effects associated with the use of antibody drugs are expected to act as a restraint for the Middle East and Asia Pacific antibody drugs market growth over the forecast period. According to an article published by the Frontiers in Immunology journal in June 2018, some of the common side effects associated with the use of immunoglobulin therapy (antibody drugs), including headache, flushing, malaise, chills, fever, fatigue, and lethargy, are transient and mild. However, immunoglobulin therapy may also cause adverse effects such as aseptic meningitis, renal impairment, arrhythmia, thrombosis, hemolytic anemia, transfusion-related acute lung injury (TRALI), and others.